https://scholars.lib.ntu.edu.tw/handle/123456789/203936
標題: | Pharmacotherapy in Acute Spinal Cord Injury 急性脊髓損傷之藥物治療 |
作者: | WANG, YEN-HO HUANG, TIEN-SHANG 王顏和 黃天祥 |
關鍵字: | spinal cord injury;steroid;neurological recovery | 公開日期: | 1999 | 卷: | v.27 | 期: | n | 起(迄)頁: | 157-82 | 來源出版物: | Journal of Rehabilitation Medicine Association Republic of China | 摘要: | TP-B AU-Wang YH AU-Huang TS TI-Pharmacotherapy in acute spinal cord injury SO-Journal of Rehabilitation Medicine Assocation ROC AB-Acute traumatic spinal cord injury (SCI), a devastating event, results in huge costs to patients and society. Current management emphasizes general supportive care and stabilization of associated spinal columnar injury to prevent worsening of the cord lesions. Most of the numerous experimental studies to investigate pathophysiological changes following acute SCI suggest a two -step mechanism of damage to the spinal cord in which the primary (direct) or mechanical injury caused by trauma initiates secondary (indirect) or progressive autodestructive injury of the cord. During recent years, free oxygen radical generation and lipid peroxidation have been implicated in the secondary injury. Several pharmacological agents have been examined in a variety of animal models. Although methylprednisolone (MP) is the major agent currently being studied, other agents are also being developed. Animal models of SCI treated with steroids in the early 1970s served as the basis for the National Acute Spinal Cord Injury Study (NASCIS) in America. he leading theory is that steroids inhibit post-SCI lipid peroxidation and enhance recovery by inhibiting the injury-induced degenerative cascade that follows. In initial trails, MP was not effective in improving the outcome. In NASCIS II, MP was given in a dosage of 30 mg/kg body weight within 3 hours of injury, followed by the administration of MP, 5.4 mg/kg/ hr, for 23 hours. This regimen produced a significant neurologic improvement in one-year follow-up when compared with placebo. The study of NASCIS III trial is intended to determine the best time for starting the MP regiment, the optimal duration of therapy, and the benefits, if any, of substituting tirilazad mesylate for MP after the initial dose. In conclusion, if the initial bolus is started within 3 hours of injury, 24-hour MP treatment is appropriate; if the bolus is not administered until 3-8 hours, treatment should be extended for 48 hours. Recently the administration of high-dose MP has become the stanard care in the optimal management of SCI. The therapy should not be given more than 8 hours after injury. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/99374 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。